An Efficacy And Safety Study Of Tanezumab For The Treatment Of Pain Associated With Chronic Abacterial Prostatitis

• Status: Completed
• Trial end date: 2010-03-17
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to determine whether tanezumab is effective in the treatment of pain associated with chronic prostatitis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Tanezumab

Criteria

Inclusion Criteria:

• Diagnosis of chronic prostatitis

• Male adults at least 18 years of age

• Moderate to severe chronic prostatitis, with an average pain score above a pre-defined level

• To use contraception.

Exclusion Criteria:

• History of symptoms for less than 3 of the last 6 months

• History of recurrent urinary tract infections, or genito-urinary cancer

• Use of finasteride or dutasteride within 6 months.

• History of hepatitis B, C or human immunodeficiency virus (HIV)